This study aimed to train a DLM to predict Alb using ECG as a novel biomarker called ECG-Alb and to explore its contribution to all-cause mortality, new-onset hypoalbuminemia, new-onset CKD, new-onset hepatitis, CVD mortality, new-onset AMI, new-onset STK, new-onset CAD, new-onset HF, and new-onset Afib in patients with normal serum Alb. This evidence concerns the gene ALB and coronary artery disorder.